The TCRs that define the specificity of our drugs recognise unique short peptides derived from proteins expressed in the target cells from cancers, inflamed tissue or infected cells. These can be from intracellular, extracellular or secreted proteins, vastly expanding the target space compared with conventional antibody approaches.

These advances enable us to address known upstream disease drivers which translates into impactful clinical improvements for patients. We identify targets that are pan-indication to address high unmet medical need and improve the lives of patients.